These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32201019)

  • 1. The Consultant's intermediary role in the regulation of molecular diagnostics in the US.
    Holloway K; Miller FA
    Soc Sci Med; 2022 Jul; 304():112929. PubMed ID: 32201019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Industry, experts and the role of the 'invisible college' in the dissemination of non-invasive prenatal testing in the US.
    Holloway K; Miller FA; Simms N
    Soc Sci Med; 2021 Feb; 270():113635. PubMed ID: 33385622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enabling Equal Access to Molecular Diagnostics: What Are the Implications for Policy and Health Technology Assessment?
    Plun-Favreau J; Immonen-Charalambous K; Steuten L; Strootker A; Rouzier R; Horgan D; Lawler M
    Public Health Genomics; 2016; 19(3):144-52. PubMed ID: 27237607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agricultural consultancy--a career choice for veterinarians.
    Taylor KL; Swan RA; Chapman HM
    Aust Vet J; 2000 Jul; 78(7):489-93. PubMed ID: 10923185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostics and personalized medicine: observations from the World Companion Diagnostics Summit.
    Curran ME; Platero S
    Pharmacogenomics; 2011 Apr; 12(4):465-70. PubMed ID: 21521019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biopharmaceutical industry perspectives on the business prospects for personalized medicine.
    Milne CP; Zuckerman R
    Per Med; 2011 Sep; 8(5):541-550. PubMed ID: 29793252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. State of the industry for drug-diagnostic development: challenge and change on the path to precision medicine.
    Milne CP; Cohen J; Chakravarthy R; Awatin J
    Per Med; 2016 Jul; 13(4):337-345. PubMed ID: 29749814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
    Roscoe DM; Hu YF; Philip R
    Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Profile: B. W. Du Gas who lives in Canada and started practicing a consultant's business which is related to nursing and is rarely found in the world].
    Kango; 1979 Jan; 31(1):126-7. PubMed ID: 368419
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical and economic challenges facing pharmacogenomics.
    Cohen J; Wilson A; Manzolillo K
    Pharmacogenomics J; 2013 Aug; 13(4):378-88. PubMed ID: 22231566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding commercial actors' engagement in policy debates on proposed e-cigarette regulation in Scotland.
    Ikegwuonu T; Hilton S; Smith KE; Buckton CH; Wong M; Weishaar HB
    Tob Control; 2022 Jul; 31(4):511-519. PubMed ID: 33771932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Personalized Medicine Coalition: goals and strategies.
    Abrahams E; Ginsburg GS; Silver M
    Am J Pharmacogenomics; 2005; 5(6):345-55. PubMed ID: 16336000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The applications of big data in molecular diagnostics.
    Wong YKE; Lam KW; Ho KY; Yu CSA; Cho WC; Tsang HF; Chu MKM; Ng PWL; Tai CSW; Chan LWC; Wong EYL; Wong SCC
    Expert Rev Mol Diagn; 2019 Oct; 19(10):905-917. PubMed ID: 31422710
    [No Abstract]   [Full Text] [Related]  

  • 16. Reimbursement and coverage challenges associated with bringing emerging molecular diagnostics into the personalized medicine paradigm.
    Ridge JR
    Per Med; 2006 Aug; 3(3):345-348. PubMed ID: 29788649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Should Ethics Consultants Weigh the Law (and other Authoritative Directives)?
    Koch P
    J Law Med Ethics; 2020 Dec; 48(4):768-777. PubMed ID: 33404326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What do external consultants from private and not-for-profit companies offer healthcare commissioners? A qualitative study of knowledge exchange.
    Wye L; Brangan E; Cameron A; Gabbay J; Klein JH; Anthwal R; Pope C
    BMJ Open; 2015 Feb; 5(2):e006558. PubMed ID: 25716174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group.
    Garfield S; Polisena J; S Spinner D; Postulka A; Y Lu C; Tiwana SK; Faulkner E; Poulios N; Zah V; Longacre M
    Value Health; 2016; 19(5):577-87. PubMed ID: 27565275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contractors with consultant's hats.
    Quimby ED
    Trustee; 1984 Feb; 37(2):26. PubMed ID: 10264906
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.